Q-omics provides the consensus-scored LINC00472 profile across patient tissues and cancer cell-line models. LINC00472 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00472 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LINC00472 RNA expression shows 17,819 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where LINC00472 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00472 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00472 survival associations across molecular data types. LINC00472 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00472 RNA expression–survival associations across cancer types. High LINC00472 expression shows unfavorable associations in PAAD, but favorable associations in KIRC, BRCA, UCS, CESC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00472 RNA expression.
This table summarizes LINC00472 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00472. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00472 shows lower tumor expression in KIRC, THCA, BLCA, COAD, KICH and LUAD. The KIRC box plot shows higher LINC00472 RNA expression in normal versus tumor tissue (log2 FC = −2.097, t-test p < 0.001).
This table shows molecular features associated with LINC00472 in patient tissues and cancer cell lines. In patient samples, LINC00472 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC00472 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in NCI60_ALL.
